Rejected at 6:35 p.m. Jan, 14, 2025 ] by mohannadkh10
Author: mohannadkh10
Co-authors: Eli.Tanenbaum , Cameron , beejumm
Related Note: 1555286309380 4
Rationale for change

Amboss: "Drugs that improve prognosis (i.e., reduce morbidity, mortality, and hospitalization rates) are beta blockers, ACEIs, ARNIs, MRAs, hydralazine with isosorbide dinitrate, and SGLT2is."

UW: 2740: "Digoxin reduces the rate of hospitalization for heart failure but has not been shown to improve mortality" Also "Diuretic, Improves symptoms & reduces hospitalization"

UW 16507
"GLP-1 agonists induce weight loss and reduce mortality associated with ASCVD", but it was mentioning it in the context of ADD-on therapy (i.e., patients with diabetes)

Entresto (sacubitril/valsartan) is increasingly emphasized, especially in board exams, as a preferred agent over ACE inhibitors and ARBs. I strongly believe it should be included in the text


Source: AMBOSS - https://next.amboss.com/us/article/7m04Sg?q=GLP-1#Z50b8daedd1c8c090e9f82808f6c9d9b4

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
Empty field
OME
Additional Resources
One by one
Empty field
#AK_Step2_v12::!Shelf::IM::no_dupes::only_step2 #AK_Step1_v12::#Pixorize::03_Pharmacology::22_Cardiovascular_(New)::04_Hydralazine #AK_Step2_v12::#UWorld::Step::2732 #AK_Step2_v12::#OME::01_Medicine::01_Cardiology::03_Heart_Failure #AK_Step3_v12::#OME::Intern_Content::Common_Medical_Problems::CHF_1:_In_the_Clinic #AK_Step2_v12::#SketchyIM::01_Cardiology::02_Heart_Failure::07_Chronic_Heart_Failure_Management_Part_2 #AK_Step2_v12::#Resources_by_rotation::IM::ome::cardio::hf #AK_Step2_v12::#UWorld::COMLEX::103504 #AK_Step2_v12::#SketchyIM::01_Cardiology::01_Ischemic_Heart_Disease::09_Post_ACS_Management #AK_Step2_v12::#Resources_by_rotation::IM::emma #AK_Step2_v12::#OME_banner #AK_Other::!AK_UpdateTags::AnKing_Image::!Subjects::Cardiology::Heart_failure #AK_Step2_v12::#Resources_by_rotation::FM::nbme #AK_Step2_v12::Original_decks::Dorian::fam::nbme #AK_Step2_v12::#Resources_by_rotation::IM::uw::cardio::cardio_zanki #AK_Step2_v12::!Shelf::#Cards_AnKing_Skipped #AK_Step2_v12::#OME_banner::Clinical::01_Cardiology::02_Heart_Failure #AK_Step2_v12::#SketchyIM::01_Cardiology::06_Blood_Pressure::02_Hypertension_Management #AK_Step2_v12::Original_decks::Dorian::im::emma #AK_Step2_v12::#Resources_by_rotation::IM::uw::cardio::cardio_dorian #AK_Step1_v12::#NinjaNerd::04_Pharmacology::01_Basics::06_Drugs_for_Heart_Failure #AK_Step2_v12::#NBME::Form09 #AK_Other::!AK_UpdateTags::AnKing_Image::Mujeeb::Heart_failure #AK_Other::#AK_Original_Decks::Step_2::Cheesy_Dorian_(M3) #AK_Step2_v12::#CMS::FM::Form_05 #AK_Step2_v12::Original_decks::Dorian::im::uw::cardio #PANCE::EOR::EM #AK_Step2_v12::#Subjects::Cardiology::03_Heart_Failure::Treatment #AK_Step2_v12::#Bootcamp::Medicine::01_Cardiology::01_Coronary_Artery_Disease::08_Cardiovascular_Disease_Risk_Assessment #AK_Step2_v12::Original_decks::Dorian::im::ome::cardio::hf #AK_Step2_v12::#SketchyIM::05_Endocrinology::01_Diabetes_Mellitus::02_Diabetes_Management #PANCE::EOR::Family_med #AK_Step2_v12::Original_decks::Zanki_Step_2::IM::Cardio #AK_Step2_v12::!Shelf::ObGyn #AK_Step2_v12::#SketchyIM::01_Cardiology::02_Heart_Failure::06_Chronic_Heart_Failure_Management_Part_1 #AK_Step1_v12::#Pixorize::03_Pharmacology::06_Cardiovascular_Pharm::22_Hydralazine #AK_Step2_v12::#B&B::02_Cardio::03_Heart_Failure::02_Heart_Failure_II #AK_Step1_v12::#Pixorize::03_Pharmacology::07_Diabetes_Drugs_(New)::09_SGLT2_Inhibitors #AK_Step2_v12::#UWorld::Step::16507 #AK_Step3_v12::#UWorld::6420 #AK_Step2_v12::#UWorld::COMLEX::28544 #AK_Step2_v12::#FirstAid::01_Cardiovascular::05_Congestive_Heart_Failure::03_Systolic_Dysfunction/Heart_Failure_with_Reduced_Ejection_Fraction #PANCE::CARDIO::heart_failure